ASRT Posts 57.9% Revenue Drop But Shares Rise Why

Assertio Holdings (ASRT) reported fiscal 2025 Q4 earnings on March 16, 2026, with revenue declining sharply but beating estimates. The company posted a wider-than-expected net loss and initiated 2026 guidance, reflecting strategic shifts toward oncology and cost optimization.

Revenue

The total revenue of Assertio HoldingsASRT+1.99% dropped by 57.9% to $13.54 million in 2025 Q4, a significant decline from $32.18 million in 2024 Q4.

Earnings/Net Income

Assertio Holdings’s losses deepened to $1.86 per share in 2025 Q4 from a loss of $0.11 per share in 2024 Q4 (1593.0% wider loss). Meanwhile, the company’s net loss widened to $-11.93 million in 2025 Q4, representing a 13.9% increase from the $-10.48 million loss recorded in 2024 Q4. The EPS result reflects a deteriorating financial position, with the substantial per-share loss underscoring operational challenges.

Price Action

The stock price of AssertioASRT+1.99% Holdings edged up 1.90% during the latest trading day, 1.73% during the most recent full trading week, and declined 1.51% month-to-date.

Post-Earnings Price Action Review

The strategy of buying Assertio Holdings (ASRT) shares after a revenue drop quarter-over-quarter on the financial report release date and holding for 30 days resulted in poor performance over the past three years. The strategy yielded a return of -24.73%, significantly underperforming the benchmark return of 51.85%. The excess return was -76.57%, and the strategy had a CAGR of -6.91%, indicating a loss over the period. The strategy also had a high maximum drawdown of 94.79% and a Sharpe ratio of -0.06, highlighting its riskiness and volatility.

CEO Commentary

Mark L. Reisenauer, CEO & Director, highlighted Rolvedon as a “long-term revenue opportunity” with “meaningful runway ahead,” emphasizing its IP protection until 2039 and integration into Assertio’s commercial platform. He acknowledged challenges in prior acquisition strategies, stating they were “no longer capital efficient,” and redirected focus to leveraging existing capabilities in oncology. Strategic priorities include executing a “comprehensive life cycle management strategy” for Rolvedon, disciplined capital allocation, and exploring business development opportunities in oncology through acquisitions or partnerships. Reisenauer expressed optimism about the company’s position, noting a “solid balance sheet” and confidence in the team’s ability to “deliver growth,” while cautioning against over-investing in lower-return assets like Sympazan.

Guidance

Assertio provided 2026 revenue guidance of $110 million to $125 million, reflecting expected Rolvedon growth post-second-quarter 2026 relabeling, offsetting declines in legacy assets like Indocin. Adjusted EBITDA guidance of $28 million to $40 million anticipates margin expansion via high-margin Rolvedon sales and structural cost savings from litigation reductions and restructuring. Ajay Patel, CFO, noted Q4 2025 cash of $63.4 million, with normalized working capital expected by April 2026. Rolvedon’s normalized quarterly shipments are projected to drive “underlying revenue growth,” while Indocin faces anticipated generic competition. SG&A expenses are expected to decline $3–5 million year-over-year, excluding stock compensation.

Additional News

Assertio recently regained Nasdaq compliance following a bid price recovery and executed a 1-for-15 reverse stock split to stabilize its shares. The company also outlined a strategic pivot from broad specialty product acquisitions to focused oncology development, leveraging its commercial infrastructure for targeted partnerships. Management emphasized Rolvedon’s integration as a core growth driver, with relabeling expected to boost sales in 2026.